Strides Pharma gets USFDA approval for skin cream
Strides Pharma’s step-down wholly-owned subsidiary, Strides Pharma Global Pte., Singapore has received approval for Triamcinolone Acetonide Cream USP from the USFDA.
The United States Food and Drug Administrator (USFDA) has given the approval for Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% which is a generic version of Triamcinolone Acetonide Cream of Mylan Pharmaceuticals Inc. The new product will be produced at the company's flagship facility in Bangalore and be marketed by Strides Pharma Inc in the US market.
Triamcinolone Acetonide Cream is indicated to treat multiple skin conditions including treatment of eczema, dermatitis, allergies, rash and also helps in reducing swelling, itching and redness that can occur in these types of conditions.
On Wednesday, the stock of Strides Pharma opened at Rs. 416.50 per share as against Tuesday’s close of Rs. 412.25. At 11:22 hours, the shares were trading at Rs. 406.35 per share, down by 1.43 per cent. The intraday high was Rs. 420 and the intraday low was Rs. 400.60 per share on the BSE. Its 52-week high was Rs. 760.73 and 52-week low was Rs. 334.10 per share on the BSE.
Meanwhile, Sensex was at 35,257.90, gaining 0.27 per cent.